- Home
- UCL vs KZR Comparison
UCL vs KZR Comparison
Compare UCL & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- KZR
- Stock Information
- Founded
- UCL 2014
- KZR 2015
- Country
- UCL Hong Kong
- KZR United States
- Employees
- UCL N/A
- KZR N/A
- Industry
- UCL Telecommunications Equipment
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- UCL Consumer Discretionary
- KZR Health Care
- Exchange
- UCL Nasdaq
- KZR Nasdaq
- Market Cap
- UCL 48.7M
- KZR 46.5M
- IPO Year
- UCL 2020
- KZR 2018
- Fundamental
- Price
- UCL $2.13
- KZR $6.38
- Analyst Decision
- UCL
- KZR Hold
- Analyst Count
- UCL 0
- KZR 2
- Target Price
- UCL N/A
- KZR $9.00
- AVG Volume (30 Days)
- UCL 378.8K
- KZR 59.6K
- Earning Date
- UCL 11-26-2024
- KZR 11-12-2024
- Dividend Yield
- UCL N/A
- KZR N/A
- EPS Growth
- UCL 169.91
- KZR N/A
- EPS
- UCL 0.11
- KZR N/A
- Revenue
- UCL $87,405,000.00
- KZR N/A
- Revenue This Year
- UCL $11.23
- KZR N/A
- Revenue Next Year
- UCL $27.52
- KZR N/A
- P/E Ratio
- UCL $18.91
- KZR N/A
- Revenue Growth
- UCL 4.73
- KZR N/A
- 52 Week Low
- UCL $0.97
- KZR $5.20
- 52 Week High
- UCL $3.30
- KZR $11.40
- Technical
- Relative Strength Index (RSI)
- UCL 62.21
- KZR 32.14
- Support Level
- UCL $1.41
- KZR $6.16
- Resistance Level
- UCL $3.30
- KZR $7.04
- Average True Range (ATR)
- UCL 0.39
- KZR 0.30
- MACD
- UCL 0.11
- KZR -0.06
- Stochastic Oscillator
- UCL 45.33
- KZR 17.89
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc provides mobile data connectivity and portable WiFi services. The business operates under uCloudlink 1.0, which focuses on cross-border travelers that need mobile data connectivity services across different countries. Under uCloudlink 2.0, provides mobile data connectivity services to local users across different MNOs in a single country. It generates revenue from the provision of data connectivity services, and the sales of terminals and sales of data related products.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.